| scholarly article | Q13442814 |
| P50 | author | Amy R Dunn | Q58588226 |
| Kristen A Stout | Q82243216 | ||
| Gary W. Miller | Q38322030 | ||
| P2093 | author name string | Ali Salahpour | |
| Kelly M Lohr | |||
| Minzheng Wang | |||
| Thomas S Guillot | |||
| P2860 | cites work | Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. | Q64856368 |
| Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents | Q70810207 | ||
| Inhibition of monoamine oxidase by d-methamphetamine | Q71514440 | ||
| Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse | Q72153646 | ||
| Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse | Q72153649 | ||
| Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration | Q73901664 | ||
| The hypothermic and sedative action of reserpine in the mouse | Q74660500 | ||
| Alpha-synuclein overexpression increases cytosolic catecholamine concentration | Q80223133 | ||
| Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine | Q22242284 | ||
| VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse | Q22242306 | ||
| Intraneuronal dopamine-quinone synthesis: A review | Q22252807 | ||
| Expression cloning of a reserpine-sensitive vesicular monoamine transporter | Q24563187 | ||
| Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration | Q28237641 | ||
| Functional identification and molecular cloning of a human brain vesicle monoamine transporter | Q28256704 | ||
| Brain dopamine-serotonin vesicular transport disease and its treatment | Q28284572 | ||
| Mitochondrial dysfunction is a primary event in glutamate neurotoxicity | Q28290602 | ||
| Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport | Q28301517 | ||
| Vesicular integrity in Parkinson's disease | Q28385737 | ||
| VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity | Q28512294 | ||
| A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter | Q28581165 | ||
| Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. | Q30432694 | ||
| Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. | Q31962185 | ||
| Lobeline inhibits the neurochemical and behavioral effects of amphetamine. | Q31963453 | ||
| Role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity | Q31992475 | ||
| Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine | Q33344779 | ||
| Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2. | Q33613631 | ||
| Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity | Q33617472 | ||
| Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus | Q33724885 | ||
| Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis | Q33862898 | ||
| Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration : early loss of TH in striosomes after methamphetamine. | Q33873281 | ||
| Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease | Q33896138 | ||
| Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo | Q33919548 | ||
| Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. | Q33961999 | ||
| Intracellular patch electrochemistry: regulation of cytosolic catecholamines in chromaffin cells. | Q34211646 | ||
| A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse | Q34527972 | ||
| Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment | Q34973698 | ||
| Dopamine is not essential for the development of methamphetamine-induced neurotoxicity. | Q35071086 | ||
| Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone. | Q35128313 | ||
| Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress | Q35153738 | ||
| Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease | Q36785396 | ||
| PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity. | Q36942673 | ||
| Altered vesicular dopamine storage in Parkinson's disease: a premature demise | Q37159961 | ||
| Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons | Q37180671 | ||
| Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons | Q37406074 | ||
| N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux | Q37589110 | ||
| Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. | Q39758343 | ||
| Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. | Q40047308 | ||
| Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage | Q40208477 | ||
| Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons. | Q40728188 | ||
| Living on the edge with too many mouths to feed: why dopamine neurons die. | Q41732813 | ||
| Weak base model of amphetamine action | Q41939997 | ||
| Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. | Q42541545 | ||
| Inhibitors of Na(+)/H(+) and Na(+)/Ca(2+) exchange potentiate methamphetamine-induced dopamine neurotoxicity: possible role of ionic dysregulation in methamphetamine neurotoxicity | Q43627948 | ||
| Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs | Q43959363 | ||
| Methamphetamine rapidly decreases mouse vesicular dopamine uptake: role of hyperthermia and dopamine D2 receptors | Q44519185 | ||
| 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis | Q44616102 | ||
| Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity | Q44654013 | ||
| Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. | Q44842402 | ||
| Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation | Q44911128 | ||
| Differential abundance of superoxide dismutase in interneurons versus projection neurons and in matrix versus striosome neurons in monkey striatum | Q45292366 | ||
| Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. | Q46083768 | ||
| Methamphetamine-induced conditioned place preference or aversion depending on dose and presence of drug | Q46404583 | ||
| Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. | Q48144142 | ||
| The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. | Q48157604 | ||
| Further studies of the role of hyperthermia in methamphetamine neurotoxicity. | Q48162569 | ||
| Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. | Q48257438 | ||
| Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum | Q48301354 | ||
| Environmental enrichment does not reduce the rewarding and neurotoxic effects of methamphetamine. | Q48314703 | ||
| The effects of methamphetamine on the production of free radicals and oxidative stress | Q48379473 | ||
| Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. | Q48478164 | ||
| The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum | Q48529338 | ||
| Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants | Q48644051 | ||
| Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers | Q48656676 | ||
| Functional architecture of the mammalian striatum: mouse vascular and striosome organization and their anatomic relationships | Q48842504 | ||
| Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. | Q48843310 | ||
| Acute neuropathological changes in the caudate nucleus caused by MPTP and methamphetamine: immunohistochemical studies | Q48964680 | ||
| Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain | Q48968033 | ||
| Simultaneous monitoring of conditioned place preference and locomotor sensitization following repeated administration of cocaine and methamphetamine. | Q51393104 | ||
| Mental depression in hypertensive patients treated for long periods with large doses of reserpine. | Q52173297 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 790-799 | |
| P577 | publication date | 2015-03-09 | |
| P1433 | published in | ACS Chemical Neuroscience | Q2819059 |
| P1476 | title | Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity | |
| P478 | volume | 6 |
| Q58730704 | Altered dopamine release and monoamine transporters in Vps35 p.D620N knock-in mice |
| Q40420206 | Association of SNPs in dopamine and serotonin pathway genes and their interacting genes with temperament traits in Charolais cows. |
| Q56977707 | DARK Classics in Chemical Neuroscience: Aminorex Analogues |
| Q41379166 | Detection of Free and Protein-Bound ortho-Quinones by Near-Infrared Fluorescence |
| Q55040513 | Does Repeated Methamphetamine Exposure at Different Regimens Cause Parkinsonian-Like Behavior in Rats? |
| Q39175231 | Escalating Methamphetamine Regimen Induces Compensatory Mechanisms, Mitochondrial Biogenesis, and GDNF Expression, in Substantia Nigra |
| Q91942521 | Genome-Wide Association Study Identifies Genomic Loci Associated With Neurotransmitter Concentration in Cattle |
| Q48433008 | Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain. |
| Q89595744 | Increased endogenous dopamine prevents myopia in mice |
| Q39294770 | Linking Stress, Catecholamine Autotoxicity, and Allostatic Load with Neurodegenerative Diseases: A Focused Review in Memory of Richard Kvetnansky |
| Q38926644 | Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease |
| Q46252209 | Methamphetamine Induces Dopamine Release in the Nucleus Accumbens Through a Sigma Receptor-Mediated Pathway. |
| Q64785696 | The usual suspects, dopamine and alpha-synuclein, conspire to cause neurodegeneration |
| Q41031814 | Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals. |
Search more.